1-2 of 2
Riemke Bouvier
Close
Sort by
Journal Articles

A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)

Caron A. Jacobson, Caroline Falvey, Riemke Bouvier, Sarah Hogan, Elizabeth Kendricken, Julia Jones, Elizabeth Grimm, Robert A. Redd, Eudocia Q Lee, Luis Gonzalez Castro, Ugonma Chukwueke, Jose McFaline Figueroa, Austin I. Kim, Alexandra Torres, Linda Ramsdell, Leslie S. Kean, Ulrike Gerdemann, Alexandre Albanese, Paula Keskula, David Meredith, Lynette Sholl, Soumya Poddar, Madison Davis, Daquin Mao, Simone Filosto, Mike Mattie, Philippe Armand, Lakshmi Nayak
Journal: Blood
Blood (2022) 140 (Supplement 1): 1060–1061.
https://doi.org/10.1182/blood-2022-165256
Published: 2022
Journal Articles

Targeting CNS Lymphoma with Intravenous Axicabtagene Ciloleucel: Evidence for Transcriptional Evolution Towards a Prominent Interferon Signature in CAR-T Cells Trafficking to the Tumor Site

Ulrike Gerdemann, James Kaminski, Alexandre Albanese, Paula Keskula, Lorenzo Cagnin, Kayla Betz, Jillian Zavistaski, Ryan A Fleming, Caroline Falvey, Riemke Bouvier, Julia Jones, Soumya Poddar, Mike Mattie, Ugonma Chukwueke, Alexandra Torres, Caron A. Jacobson, Lakshmi Nayak, Leslie S. Kean
Journal: Blood
Blood (2022) 140 (Supplement 1): 408–409.
https://doi.org/10.1182/blood-2022-166645
Published: 2022